The FINANCIAL — Novartis on December 8 announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with ...

If Novartis wants to be a respiratory giant in Europe, it’s going to have to weasel market share away from GlaxoSmithKline. Now it has some new data it’s hoping can help on that front. Sunday, the New ...

A new study suggests COPD patients experience improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid containing combination therapies to Novartis’ ...

Novartis is looking to snatch patients from GlaxoSmithKline with Advair rival Ultibro Breezhaler. And it has some new data in hand that could help convince doctors and patients to make the switch.

New data reveal that Ultibro (glycopyrronium bromide/ indacaterol) was superior to Seretide (salmeterol/fluticasone) in reducing flare ups in patients with moderate ...

TOKYO and LONDON, March 21, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) confirms that Ultibro® Breezhaler® and Seebri® Breezhaler® have been launched by Novartis in China ...

QUANTIFY study met primary endpoint demonstrating non-inferiority of Ultibro®Breezhaler® vs tiotropium 18 mcg plus formoterol 12 mcg in improving health-related quality of life outcomes[1],[2] ...

In the CRYSTAL study, patients with moderate COPD who were switched to Ultibro Breezhaler from their previous therapy (LABA+ICS * or LABA or LAMA***) experienced superior improvements in lung function ...

Basel, December 8, 2016 - Novartis today announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with ...